Cantor Fitzgerald Weighs in on Rezolute FY2026 Earnings

Key Points

• Cantor Fitzgerald has adjusted its FY2026 earnings estimate for Rezolute, projecting a loss of ($0.91) per share, slightly worse than the previous estimate of ($0.90).
• Rezolute reported a quarterly loss of ($0.26) per share, missing the consensus estimate of ($0.23).
• Multiple analysts maintain a positive outlook on Rezolute, with several rating it as a "buy" and price targets ranging up to $20.00.

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2026 earnings estimates for Rezolute in a note issued to investors on Monday, September 29th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($0.91) for the year, down from their prior estimate of ($0.90). The consensus estimate for Rezolute's current full-year earnings is ($0.93) per share.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its earnings results on Wednesday, September 17th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03).

Several other equities analysts have also issued reports on the company. Guggenheim reaffirmed a "buy" rating and set a $15.00 price objective on shares of Rezolute in a report on Monday, September 22nd. Maxim Group raised their price target on Rezolute from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Thursday, September 18th. Wedbush reiterated an "outperform" rating and issued a $12.00 price objective on shares of Rezolute in a research note on Thursday, September 18th. BTIG Research restated a "buy" rating and set a $17.00 target price on shares of Rezolute in a research report on Thursday, September 18th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $14.00 target price on shares of Rezolute in a report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $14.50.

Rezolute Price Performance

Shares of RZLT opened at $9.40 on Wednesday. Rezolute has a 1-year low of $2.21 and a 1-year high of $9.56. The stock has a market cap of $853.62 million, a PE ratio of -9.69 and a beta of 0.02. The firm has a fifty day moving average price of $7.12 and a 200 day moving average price of $4.99.

Institutional Investors Weigh In On Rezolute

Several hedge funds have recently modified their holdings of RZLT. BNP Paribas Financial Markets acquired a new position in Rezolute in the 2nd quarter valued at $25,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Rezolute in the second quarter valued at about $30,000. Legal & General Group Plc acquired a new position in shares of Rezolute during the second quarter worth about $32,000. Jeppson Wealth Management LLC purchased a new position in Rezolute during the first quarter worth about $35,000. Finally, Raymond James Financial Inc. purchased a new position in Rezolute during the second quarter worth about $46,000. 82.97% of the stock is owned by institutional investors and hedge funds.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.